European CHMP recommends license extension of blinatumomab (Blincyto) for acute lymphoblastic leukaemia

The licence extension is for use in patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia who have failed treatment with at least two tyrosine kinase inhibitors and have no alternative treatment options.

Source:

European Medicines Agency